References
- Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Global Burden of Disease Cancer Collaboration, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–548. doi:https://doi.org/10.1001/jamaoncol.2016.5688.
- Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol. 2002;167(1):103–111. doi:https://doi.org/10.1016/S0022-5347(05)65392-X.
- Buhmeida A, Pyrhönen S, Laato M, Collan Y. Prognostic factors in prostate cancer. Diagn Pathol. 2006;1:4. doi:https://doi.org/10.1186/1746-1596-1-4.
- Hashmi AA, Hashmi SK, Irfan M, Asif H, Nisar L, Naeem M, et al. Prognostic utility of epidermal growth factor receptor (EGFR) expression in prostatic acinar adenocarcinoma. Appl Cancer Res. 2019;39:2. doi:https://doi.org/10.1186/s41241-018-0069-5.
- Giannico GA, Arnold SA, Gellert LL, Hameed O. New and emerging diagnostic and prognostic immunohistochemical biomarkers in prostate pathology. Adv Anat Pathol. 2017;24(1):35–44. doi:https://doi.org/10.1097/PAP.0000000000000136.
- Hashmi AA, Khan EY, Irfan M, Ali R, Asif H, Naeem M, et al. ERG oncoprotein expression in prostatic acinar adenocarcinoma; clinicopathologic significance. BMC Res Notes. 2019;12(1):35. doi:https://doi.org/10.1186/s13104-019-4090-x.
- Hashmi AA, Mudassir G, Irfan M, Hussain ZF, Hashmi SK, Asif H, et al. Prognostic significance of high androgen receptor expression in prostatic acinar adenocarcinoma. Asian Pac J Cancer Prev. 2019;20(3):893–896. doi:https://doi.org/10.31557/APJCP.2019.20.3.893.
- Khochikar M. Newly proposed prognostic grade group system for prostate cancer: genesis, utility and its implications in clinical practice. Curr Urol Rep. 2016;17(11):80. doi:https://doi.org/10.1007/s11934-016-0635-x.
- Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol. 2016;11:25. doi:https://doi.org/10.1186/s13000-016-0478-2.
- Tosoian JJ, Mamawala M, Epstein JI, Landis P, Macura KJ, Simopoulos DN, et al. Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur Urol. 2020;77(6):675–82. doi:https://doi.org/10.1016/j.eururo.2019.12.017.
- Iczkowski KA, Torkko KC, Kotnis GR, Storey Wilson R, Huang W, Wheeler TM, et al. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol. 2011;136(1):98–107. doi:https://doi.org/10.1309/AJCPZ7WBU9YXSJPE.
- Fajardo DA, Miyamoto H, Miller JS, Lee TK, Epstein JI. Identification of Gleason pattern 5 on prostatic needle core biopsy: frequency of underdiagnosis and relation to morphology. Am J Surg Pathol. 2011;35(11):1706–1711. doi:https://doi.org/10.1097/PAS.0b013e318228571d.
- Mathieu R, Moschini M, Beyer B, Gust KM, Seisen T, Briganti A, et al. Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study. Prostate Cancer Prostatic Dis. 2017;20(2):197–202. doi:https://doi.org/10.1038/pcan.2016.66.
- Inamura K. Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. Oncotarget. 2018;9(18):14723–14737. doi:https://doi.org/10.18632/oncotarget.24515.
- Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519. doi:https://doi.org/10.1136/bmj.k3519.
- Ferro M, Lucarelli G, Bruzzese D, Perdonà S, Mazzarella C, Perruolo G, et al. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. Anticancer Res. 2015;35(2):1017–1023.
- Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol. 2012;61(3):455–466. doi:https://doi.org/10.1016/j.eururo.2011.10.038.